Table 3 Prevalence of OSFED and UFED in community samples
OSFED (all) (%) | S-BN (%) | S-BED (%) | A-AN (%) | UFED (%) | |
|---|---|---|---|---|---|
Lifetime prevalence | |||||
Mustelin et al. [106] | F: 0.6 | F: 0.9 | |||
Fairweather-Schmidt [55] | 5.0 | ||||
Micali et al. [97] | F: 7.6 | F: 1.4 | F: 0.9 | F: 1.7 | F: 0.1 |
Mohler-kuo et al. [103] * | 1.2 F: 0.9 M: 1.6 | ||||
Lahteenmaki et al. [85] | 3.2 F: 6.0 | ||||
Preti et al. [115] | 0.7 F: 0.6 M: 0.9 | ||||
Le Grange et al. [89] | A: 4.8 a: 4.6 | ||||
Nagl et al. [108] | G: 2.2 B: 0.7 | ||||
Isomaa et al. [76] | 7.7 | 1.3 | |||
3-Month prevalence | |||||
Hay et al. [72] | 3.2 | 0.5 | 0.4 | 2.5 | 10.4 |
Hay et al. [73] | 8.2 | 0.7 | 6.9 | 1.4 | |
Point prevalence | |||||
Mitchison et al. [150] | 11.2 G: 14.5 B: 8.5 | 2.1 G: 2.7 B: 1.2 | 0.3 G: 0.5 B: 0 | 2.9 G: 4.8 B: 1.2 | 6.3 G: 14.5 B: 8.5 |
Allen et al. [30] | G: 4.1 B: 0.9 | ||||
Flament et al. [60] | G: 6.6 B: 1.9 | G: 3.7 B: 0.7 | G: 1.4 B: 0.4 | ||
Smink et al. [123] | G: 0.3 B: 0 | ||||
Rozzell et al. [118] | 0.7 G: 0.7 B: 0.7 | 0.1 G: 0 B: 0.2 | 0.6 G: 0.6 B: 0.5 | ||